Accelerator Life Science Partners is a venture capital firm established in 2003, with headquarters in Seattle, Washington, and additional offices in New York City and San Diego. The firm specializes in the incubation and early-stage investment in life sciences, biotechnology, and therapeutics companies, focusing primarily on seed and start-up ventures. Accelerator Life Science Partners does not engage in subsequent financing rounds, typically investing up to $2 million per company and maintaining investments for 12 to 24 months. The firm provides a wide range of business, scientific, and financial resources to support the development and commercialization of innovative biotechnology discoveries. Its investment activities are primarily concentrated in New York City and Seattle.
Proniras Corporation is a preclinical-stage biotechnology company based in Seattle, Washington, focused on developing innovative small-molecule therapeutics for neurological disorders. The company is known for its parenteral medical countermeasure drug, tezampanel, which shows promise in treating seizures and brain injuries. Proniras has demonstrated preclinical efficacy in addressing nerve agent-induced seizures, particularly in studies involving rodents exposed to the highly toxic chemical weapon soman. Founded in 2016, the company aims to address significant unmet medical needs in the central nervous system by antagonizing glutamate signaling, thereby advancing medical research and drug discovery in this critical area.
Automera
Series A in 2023
Automera is engaged in the development of innovative therapeutic methods for drug creation. The company specializes in an autophagy-targeting drug designed to address specific diseases. Utilizing advanced computational chemistry, artificial intelligence, and quantum molecular dynamics, Automera's technology focuses on designing chimeric small molecules. These molecules are engineered to bind simultaneously to autophagy processes and specific disease targets, functioning as natural defense mechanisms against viruses and bacteria. This approach enables clients to identify and develop effective drugs that harness the body's autophagy capabilities.
KayoThera
Series A in 2023
KayoThera is a biotechnology company based in Princeton, New Jersey, focused on developing therapeutics for late-stage and metastatic cancers. Founded in 2019, the company aims to create first-in-class immuno- and targeted therapies that target a key enzyme responsible for protecting cancer cells, as well as depleting regulatory T-cells. This innovative approach seeks to enhance the effectiveness of existing treatments, such as chemotherapy and immunotherapy, thereby offering new hope to patients with previously incurable cancers. KayoThera's mission is centered on driving breakthroughs in cancer treatment and improving patient outcomes.
KayoThera
Series A in 2022
KayoThera is a biotechnology company based in Princeton, New Jersey, focused on developing therapeutics for late-stage and metastatic cancers. Founded in 2019, the company aims to create first-in-class immuno- and targeted therapies that target a key enzyme responsible for protecting cancer cells, as well as depleting regulatory T-cells. This innovative approach seeks to enhance the effectiveness of existing treatments, such as chemotherapy and immunotherapy, thereby offering new hope to patients with previously incurable cancers. KayoThera's mission is centered on driving breakthroughs in cancer treatment and improving patient outcomes.
Lydian Neurosciences
Pre Seed Round in 2021
Lydian Neurosciences focusses on developing small molecules for the treatment of sleep disorders.
Rodeo Therapeutics
Venture Round in 2018
Rodeo Therapeutics Corp. is a drug development company based in Seattle, Washington, focused on creating novel small molecule therapies aimed at treating inflammatory bowel disease and enhancing blood cell reconstitution after bone marrow transplants. Founded in 2017, the company specializes in targeting specific enzymes and biological pathways that are vital for tissue repair and regeneration. Its therapies work by increasing tissue levels of prostaglandin PGE2 through the inhibition of a prostaglandin-degrading enzyme, thereby facilitating tissue regeneration and protecting against conditions such as colitis. Rodeo Therapeutics is dedicated to advancing treatments that improve patient outcomes in various medical conditions related to tissue damage and recovery.
Magnolia NeuroSciences
Series A in 2018
Magnolia Neurosciences Corporation is a New York-based company focused on drug discovery and development, specifically targeting neuroprotective therapies for central nervous system diseases and neurodegeneration. Established in 2018, the company aims to create proprietary small molecule therapeutics that prevent neuronal cell death, offering new treatment options for patients with neurodegenerative disorders and related conditions. Magnolia Neurosciences was founded to advance technologies developed at The University of Texas MD Anderson Cancer Center’s Therapeutics Discovery Division and the Neurodegeneration Consortium. Through its innovative approach, the company seeks to address significant medical needs in the field of neurology.
Coba Therapeutics
Pre Seed Round in 2018
Coba Therapeutics is a developer of novel therapeutics designed to help in the treatment of metabolic diseases.
Proniras
Venture Round in 2017
Proniras Corporation is a preclinical-stage biotechnology company based in Seattle, Washington, focused on developing innovative small-molecule therapeutics for neurological disorders. The company is known for its parenteral medical countermeasure drug, tezampanel, which shows promise in treating seizures and brain injuries. Proniras has demonstrated preclinical efficacy in addressing nerve agent-induced seizures, particularly in studies involving rodents exposed to the highly toxic chemical weapon soman. Founded in 2016, the company aims to address significant unmet medical needs in the central nervous system by antagonizing glutamate signaling, thereby advancing medical research and drug discovery in this critical area.
ApoGen Biotechnologies
Pre Seed Round in 2015
ApoGen Biotechnologies, Inc., founded in 2014 and located in Seattle, Washington, is dedicated to developing innovative therapeutics aimed at addressing the challenges of cancer treatment, particularly the issue of drug resistance. The company focuses on targeting the key drivers of genomic mutations in cancer cells, which are central to tumor evolution and the development of resistance to existing therapies. By addressing the chronic mutations in cancer genomes, ApoGen aims to improve treatment efficacy, reduce cancer recurrence and metastasis, and enhance overall patient survival. The company's approach represents a shift from traditional therapies, providing new hope in the ongoing battle against cancer.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.